Suppr超能文献

冠状动脉搭桥手术后的抗生素预防与艰难梭菌感染风险

Antibiotic prophylaxis and risk of Clostridium difficile infection after coronary artery bypass graft surgery.

作者信息

Poeran Jashvant, Mazumdar Madhu, Rasul Rehana, Meyer Joanne, Sacks Henry S, Koll Brian S, Wallach Frances R, Moskowitz Alan, Gelijns Annetine C

机构信息

Department of Population Health Science and Policy, Institute for Healthcare Delivery Science, Icahn School of Medicine at Mount Sinai, New York, NY.

Department of Population Health Science and Policy, Institute for Healthcare Delivery Science, Icahn School of Medicine at Mount Sinai, New York, NY.

出版信息

J Thorac Cardiovasc Surg. 2016 Feb;151(2):589-97.e2. doi: 10.1016/j.jtcvs.2015.09.090. Epub 2015 Sep 28.

Abstract

OBJECTIVE

Antibiotic use, particularly type and duration, is a crucial modifiable risk factor for Clostridium difficile. Cardiac surgery is of particular interest because prophylactic antibiotics are recommended for 48 hours or less (vs ≤24 hours for noncardiac surgery), with increasing vancomycin use. We aimed to study associations between antibiotic prophylaxis (duration/vancomycin use) and C difficile among patients undergoing coronary artery bypass grafting.

METHODS

We extracted data on coronary artery bypass grafting procedures from the national Premier Perspective claims database (2006-2013, n = 154,200, 233 hospitals). Multilevel multivariable logistic regressions measured associations between (1) duration (<2 days, "standard" vs ≥2 days, "extended") and (2) type of antibiotic used ("cephalosporin," "cephalosporin + vancomycin," "vancomycin") and C difficile as outcome.

RESULTS

Overall C difficile prevalence was 0.21% (n = 329). Most patients (59.7%) received a cephalosporin only; in 33.1% vancomycin was added, whereas 7.2% received vancomycin only. Extended prophylaxis was used in 20.9%. In adjusted analyses, extended prophylaxis (vs standard) was associated with significantly increased C difficile risk (odds ratio, 1.43; confidence interval, 1.07-1.92), whereas no significant associations existed for vancomycin use as adjuvant or primary prophylactic compared with the use of cephalosporins (odds ratio, 1.21; confidence interval, 0.92-1.60, and odds ratio, 1.39; confidence interval, 0.94-2.05, respectively). Substantial inter-hospital variation exists in the percentage of extended antibiotic prophylaxis (interquartile range, 2.5-35.7), use of adjuvant vancomycin (interquartile range, 4.2-61.1), and vancomycin alone (interquartile range, 2.3-10.4).

CONCLUSIONS

Although extended use of antibiotic prophylaxis was associated with increased C difficile risk after coronary artery bypass grafting, vancomycin use was not. The observed hospital variation in antibiotic prophylaxis practices suggests great potential for efforts aimed at standardizing practices that subsequently could reduce C difficile risk.

摘要

目的

抗生素的使用,尤其是种类和时长,是艰难梭菌一个关键的可改变风险因素。心脏手术备受关注,因为预防性抗生素推荐使用48小时或更短时间(非心脏手术为≤24小时),且万古霉素的使用呈上升趋势。我们旨在研究冠状动脉搭桥术患者中抗生素预防(时长/万古霉素使用情况)与艰难梭菌感染之间的关联。

方法

我们从全国Premier Perspective索赔数据库(2006 - 2013年,n = 154,200,233家医院)中提取了冠状动脉搭桥术的数据。多水平多变量逻辑回归分析衡量了(1)时长(<2天,“标准”时长 vs ≥2天,“延长”时长)以及(2)所使用抗生素的类型(“头孢菌素”、“头孢菌素 + 万古霉素”、“万古霉素”)与以艰难梭菌感染为结局之间的关联。

结果

艰难梭菌总体患病率为0.21%(n = 329)。大多数患者(59.7%)仅接受了头孢菌素治疗;33.1%的患者加用了万古霉素,而7.2%的患者仅接受万古霉素治疗。20.9%的患者采用了延长预防。在调整分析中,延长预防(与标准预防相比)与艰难梭菌感染风险显著增加相关(比值比,1.43;置信区间,1.07 - 1.92),而与使用头孢菌素相比,使用万古霉素作为辅助或主要预防性用药并无显著关联(比值比分别为1.21;置信区间,,0.92 - 1.60,以及1.39;置信区间,0.94 - 2.05)。在延长抗生素预防的比例(四分位间距,2.5 - 35.7)、辅助使用万古霉素的比例(四分位间距,4.2 - 61.1)以及仅使用万古霉素的比例(四分位间距,2.3 - 10.4)方面,医院间存在很大差异。

结论

虽然冠状动脉搭桥术后延长抗生素预防与艰难梭菌感染风险增加相关,但万古霉素的使用并非如此。观察到的医院在抗生素预防措施方面的差异表明,旨在规范预防措施从而降低艰难梭菌感染风险的努力具有很大潜力。

相似文献

引用本文的文献

5
: Infections, Animal Modeling, and Therapeutics.感染、动物模型与治疗学
Cells. 2023 Jan 3;12(1):199. doi: 10.3390/cells12010199.

本文引用的文献

2
Management practices and major infections after cardiac surgery.心脏手术后的管理实践和主要感染。
J Am Coll Cardiol. 2014 Jul 29;64(4):372-81. doi: 10.1016/j.jacc.2014.04.052.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验